Clinical trials: Cancer Disease Progression
High Grade Anal Canal Intraepithelial Neoplasia, High Grade Vulvar Squamous Intraepithelial Lesion
HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions
This phase IV trial studies how well human papillomavirus (HPV) vaccine therapy works in interrupting progression in patients with high-grade vulvar or anal lesions.
- Trial name
- NCT03051516
- Testing
- Laboratory Biomarker Analysis, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
- Where
- 2 sites in United States
- Volunteers
- 188 people
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer, Breast Cancer Treatment Related Lymphedema
Early Intervention
This research study is a Pilot Study examining the use of a compression sleeve with embedded sensor to prevent lymphedema.
- Trial name
- NCT05326165
- Testing
- Juzo Compression Sleeve and Glove, Compression Sleeve Sensor
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
This single arm study will assess the efficacy and safety of a combination of modified FOLFIRI (irinotecan, 5-FU and leucovirin), Avastin and cetuximab in patients with previously untreated metastatic colorectal cancer.
- Trial name
- NCT00577109
- Testing
- bevacizumab [Avastin], Irinotecan, Leucovorin
- Where
- 3 sites in Brazil
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma, Gastric Cancer
Combination of TATE and PD-1 Inhibitor in Liver Cancer
This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab).
- Trial name
- TATE-PD1 (NCT03259867)
- Testing
- Nivolumab Injectable Product, Trans-arterial tirapazamine embolization
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Teclison Ltd.
Untreated Chronic Lymphocytic Leukemia
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of Acalabrutinib versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.
- Trial name
- NCT04075292
- Testing
- Acalabrutinib, Rituximab, Chlorambucil
- Where
- 46 sites in China, Philippines and 3 more
- Volunteers
- 155 people
- Sponsor
- AstraZeneca
Pancreatic Cancer
TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)
This is an open-label, non-randomized, sequentially enrolling single arm phase II trial to evaluate the activity of TAS-102 in previously treated metastatic and locally advanced unresectable pancreatic cancer after progression…
- Trial name
- NCT02921737
- Testing
- TAS-102
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Florida
Cancer
Demographics, Clinical Outcomes, and Physician Attitudes in Patients Who Have Received The MiCK Assay (CorrectChemo)
Recently an automated test for measuring cancer cell death in the presence of chemotherapy has been developed. This test has been called the MiCK assay during the ten year development phase and is now called Correct Chemo.
- Trial name
- NCT02137811
- Testing
- MICK Assay
- Where
- 2 sites in United States, Canada
- Sponsor
- Pierian Biosciences
NSCLC, Stage I, II, IIIA, IIIB, Surgery
Pronostic and Predictive Value of EMT in Localized Lung Cancer
The goal of the present research is to identify an "EMT signature", associated with long term disease-free survival after surgery in NSCLC.
- Conditions
- NSCLC, Stage I, II, IIIA, IIIB, Surgery, Progression, Epithelial Mesenchymal Transition
- Trial name
- TWISTlung (NCT03509779)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- European Georges Pompidou Hospital
D010051, Ovarian Cancer
Validation of ESGO Quality Indicators in Advanced Ovarian Cancer Surgery
This study, organized by the European Society of Gynaecological Oncology (ESGO), evaluates the clinical impact of adherence to ten ESGO-established quality indicators (QIs) in advanced ovarian cancer surgery.
- Conditions
- D010051, Ovarian Cancer, Advanced-stage Ovarian Cancer, FIGO Stages III and IV
- Trial name
- retroESGO ov1 (NCT07567573)
- Testing
- Preoperative Evaluations, Cytoreductive Surgery, Perioperative Management
- Where
- Belgium
- Volunteers
- 11,383 people
- Sponsor
- European Society of Gynaecological Oncology
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This 2 arm study will evaluate the efficacy, safety, and pharmacokinetics of Tarceva and that of standard of care chemotherapy in patients with advanced, recurrent, or metastatic NSCLC experiencing disease progression after…
- Trial name
- NCT00556322
- Testing
- Alimta or Taxotere, erlotinib [Tarceva]
- Where
- 123 sites in Australia, Austria and 25 more
- Volunteers
- 424 people
- Sponsor
- Hoffmann-La Roche
Bone Marrow Transplant Infection, Infection in Marrow Transplant Recipients
Respiratory Syncytial Virus - RSV Protocol
The goal of this clinical research study is to learn if ribavirin can help to control RSV in patients with immune systems that have been weakened by a stem cell transplant.
- Conditions
- Bone Marrow Transplant Infection, Infection in Marrow Transplant Recipients, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Pneumonia
- Trial name
- NCT01502072
- Testing
- Ribavirin
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Brain Metastases
A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy
To learn if 18F-Fluciclovine (Axumin) PET-CT scans can be used to better detect brain metastatic lesions in patients who are receiving immunotherapy.
- Trial name
- NCT06015295
- Testing
- 18F-Fluciclovine (Axumin), Pet Scan
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer, Psychosocial Functioning
Body Composition and Psychosocial Factors in ICI-Treated Cancer Patients
Evaluation of the effects of body composition, psychosocial factors, and drug-related problems on clinical progression (such as toxicity, treatment response, and quality of life) in cancer patients treated with immune checkpoint…
- Conditions
- Cancer, Psychosocial Functioning, Treatment Side Effects, Cachexia
- Trial name
- NCT07130981
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Hacettepe University
SCLC, Limited Stage
A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy
This study aims to evaluate the efficacy and safety of adebrelimab consolidation therapy after progression-free response of concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer.
- Trial name
- ARL-LS-SCLC (NCT07559786)
- Testing
- CCRT(Employed residual field irradiation(RFI)), CCRT(Involved-Field Radiotherapy (IFRT))
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Henan Cancer Hospital
Prostate Cancer
Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer
The purpose of this study is to assess the safety of the second cycle of DCVAC/PCa in patients who completed the first cycle of DCVAC/PCa in the clinical trial SP003 without an objective progression of the disease.
- Trial name
- NCT02137746
- Testing
- Dendritic Cells DCVAC/PCa
- Where
- 7 sites in Czechia
- Volunteers
- 24 people
- Sponsor
- SOTIO a.s.
Dupuytren Contracture, Disease Progression
Natural Disease Progress of Dupuytren Disease
Dupuytren disease (DD) is a progressive fibromatosis of the palmar fascias of the hand and fingers, which may lead to extension deficits of the fingers.
- Trial name
- DD (NCT01923103)
- Where
- Netherlands
- Volunteers
- 261 people
- Sponsor
- University Medical Center Groningen
Lung Cancer, Esophageal Cancer
A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)
At present, the treatment methods for recurrent cancers are very limited. The immune checkpoint inhibitors (ICBs) is a promising new directions for recurrent lung cancer/ esophageal cancer / cervical cancer, but the clinical…
- Conditions
- Lung Cancer, Esophageal Cancer, Cervical Cancer
- Trial name
- NCT06232083
- Testing
- PLDR+Cardunizumab
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Anhui Provincial Hospital
Prostate Cancer
Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer
This is a long-term prospective registry study to determine whether Prolaris testing in patients with favorable intermediate risk prostate cancer influences physician management decisions toward conservative treatment in patients…
- Trial name
- NCT03290508
- Testing
- Prolaris Testing
- Where
- 34 sites in United States
- Volunteers
- 524 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Medullary Thyroid Cancer
SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer
A mono centre study to evaluate the efficacy of SOM230 in patients with progressive metastatic or postoperative persistent medullary thyroid cancer.
- Trial name
- NCT01625520
- Testing
- SOM230 alone or in combination with RAD001.
- Where
- Italy
- Volunteers
- 19 people
- Sponsor
- Federico II University
Mantle-cell Lymphoma
Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT
1. Primary endpoint: Time to relapse/progression (TTP) after achieving a complete or partial response with the (R-GemOxD)-induction therapy 2. Secondary endpoints: 1.
- Trial name
- MAN2 (NCT02267915)
- Testing
- subcutaneous Rituximab
- Where
- 15 sites in Spain
- Volunteers
- 36 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.